NEW YORK CITY, NY / ACCESSWIRE / December 20, 2018 / Dwight Egan, CEO of Co-Diagnostics Inc, (NASDAQ: CODX) a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, discussed the expectation for sales before the end of 2018 in a virtual investor conference earlier this month. The discussion included the following milestones:
First Quarter 2018
• February 2018: The Company announced positive results in SNP multiplex tests. Months later this was revealed to have been part of an ongoing research and development study with LGC, Biosearch and helped to set the stage for a subsequent license agreement.
Second Quarter 2018
• June 2018: The flagship technology platform - CoPrimers™ - was used in a research project with Stanford University; the Company considered this to be an important external validation of the innovation of the technology.
• June 2018: Co-Diagnostics announces major milestone in scientific advancement of its CoPrimer™ technology, demonstrating its potential in multiplex SNP genotyping applications.
Third Quarter 2018
• July 2018: Co-Diagnostics received CE Mark for Logix Smart™ Tuberculosis Test Kit, allowing sale of the product in all countries and jurisdictions that accept CE markings as valid regulatory approval for in vitro diagnostics.
• September 2018: Co-Diagnostics expanded target markets to include Central and South America.
Fourth Quarter 2018
• October 2018: Co-Diagnostics expanded suite of intellectual property by receiving US patent protection for its flagship CoPrimer™ technology, opening the door for future license agreements of the technology and offering primer design services for PCR tests built on the platform.
• October 2018: Co-Diagnostics received CE Mark for its Logix Smart™ Zika Test Kit, expected to facilitate sale of the product in all countries and jurisdictions that accept CE markings as valid regulatory approval for in vitro diagnostics.
• October 2018: Co-Diagnostics signed license agreement with LGC, Biosearch for use of CoPrimer technology for the AgBio market, seen as a major industry validation of the technology in multiplexing and SNP detection applications.
• November 2018: Co-Diagnostics launched new website to focus on promotion and sale of its market-ready products and services.
• November 2018: Co-Diagnostics announced exclusive distributor agreement in the Dominican Republic and conducted training and sales seminars with nearly 20 labs and hospitals, setting up near-term sales potential.
• December 2018: Co-Diagnostics announces expanded international licensing and revenue opportunities following receipt of UK patent for RapidProbe™ design technology.
Mr. Egan remarked: "These milestones, when taken together as a whole, tell a very exciting story of our progress and potential. Our progress can be seen as moving forward in three primary areas, which all support and strengthen each other. The first two areas are: building relationships with major players in the diagnostics and PCR industry, and the development of sales channels (plus IVD regulatory approvals for two major diagnostics). These growth areas have direct revenue potential that we anticipate very shortly, in some cases before the end of this year.
And these two avenues are both supported by, and also continue to drive, the third area, that of continued scientific advancements of our core technology. These advancements have not only been instrumental in shoring up our relationships with several key strategic partners, but they have also opened the door for additional product development, including entrees into liquid biopsy, next-gen sequencing, and of course the AgBio industry.
As the technological advancements continue to grow, they in turn open more doors with more partners, which drives more advancements, which allows for a wider range of tests, products, and services for our customers."
Access to an archived version of the conference is available through the Company's Events and Presentations page.
Access to the Wall Street Club Interview remains available here
About The Wall Street Club:
The Wall Street Club (WSC) is a financial digital media company whose focus is to provide readers with news and content on the latest trends and happenings in the financial industry. WSC writes about stocks in both free and paid content. WSC accepts sole responsibility for the content and distribution of the foregoing release.
Disclaimer
The information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained in this analysis reflect our current judgement and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor's or other person's reliance on or use of this analysis. This analysis is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security, although members of the Wall Street Club may at times hold a position in the company covered within the article. Past gains are not a representative of future gains. The opinions herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words "anticipate," "intend," "estimate," "believe," "expect," "plans," "should," "potential," "forecast," and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company's actual results could differ materially from those described in any forward-looking statements contained herein. The Wall Street Club is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk.
Press Contact:
The Wall Street Club
SOURCE: Co-Diagnostics Inc,
View source version on accesswire.com:
https://www.accesswire.com/531085/Co-Diagnostics-Inc--End-of-Exciting-Year-Revenues-More-Excitement-Ahead-in-2019
